Archived regional presentations
Archived presentations
Review presentations, summaries and other documents from previous regional meetings:
Spring 2019 Public Comment Presentations
Discussion agenda
- Eliminate the Use of Donation Service Areas (DSAs) in Thoracic Distribution (Thoracic Organ Transplantation Committee)
- Eliminate the Use of Regions in VCA Distribution (VCA Transplantation Committee)
- Ethical Implications of Multi-Organ Transplants (Ethics Committee)
- Expedited Placement of Livers (OPO Committee)
- Guidance on Effective Practices for Broader Distribution (Operations & Safety Committee)
- MELD Exception Scores during NLRB Transition (Executive Committee)
- Removal of DSA and Region from Kidney and Pancreas Distribution (Kidney & Pancreas Transplantation Committees)
- Split Liver Variance (Liver and Intestinal Transplantation Committee)
Non-discussion agenda
- Modify HOPE Act Variance to Include Other Organs (Ad Hoc Disease Transmission Advisory Committee)
- Clarifications on Reporting Maintenance Dialysis (Living Donor Committee)
Spring 2019 Committee Presentations
- Liver and Intestinal Organ Transplantation Committee (presented at meeting)
- Pediatric Committee (presented at meeting)
- Disease Transmission Advisory Committee (presented at meeting)
- Histocompatibility Committee
- Patient Affairs Committee
- Transplant Coordinators Committee
- Vascularized Composite Allograft Transplantation Committee
Fall 2018 Public Comment Presentations
Fall 2018 Committee Presentations
- Histocompatibility
- Liver
- Membership and Professional Standards
- Minority Affairs Committee
- Organ Procurement Organization
- Patient Affairs and Transplant Coordinators (Improving the committee structure)
- Pediatric
- Thoracic
- Transplant Administrators
- Transplant Clinical Coordinators
- Vascular Composite Allograft
Spring 2018: Public comment presentations
Non-discussion agenda
- Ethics – Manipulation of the Waitlist Priority of the Organ Allocation System through the Escalation of Medical Therapies
- VCA – Align VCA Transplant Program Membership Requirements with Requirements of Other Solid Organ Transplant Programs
- VCA – Guidance on Optimizing VCA Recovery from Deceased Donors
- Operations and Safety – Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB
- OPO – Guidance on Requested Deceased Donor Information
- Thoracic – Review Board Guidance for Hypertrophic and Restrictive Cardiomyopathy Exception Requests
- Thoracic – Modification of the Lung Transplant Follow-up Form (TRF) to Better Characterize Longitudinal Change in Lung following Transplantation
Discussion agenda
- Thoracic – Modification to the Distribution of Deceased Donor Lungs
- OPO – Expedited Placement Concept Paper
- DTAC – Clarify Informed Consent Policy for Transmittable Diseases
- OSC – Extra Vessels: Reducing Reporting Burdens & Clarifying Policies
- Pancreas – Change Waiting Time Criteria for Kidney-Pancreas Candidates
- MPSC – Appendix L Revisions
- Executive – 2018-2021 OPTN Strategic Plan
- Executive – Improving the OPTN/UNOS Committee Structure
Spring 2018: Committee presentations
Fall 2017: Public comment presentations
Non-discussion agenda
- Ethics – Living Organ Donation by Persons with Certain Fatal Diseases Who Meet the Criteria to Be Living Organ Donors
- Histocompatibility – Review of HLA Tables (2016)
- MPSC – Addressing Approved Transplant Fellowship Training Programs Bylaws
- Minority Affairs – Guidance for Transplant Program Participation in the Transplantation of non-A1/non-A1B (A2/A2B) Donor Kidneys into Blood Group B Candidates
- Pancreas – Guidance on the Benefits of Pancreas After Kidney (PAK) Transplantation
- Pediatric – Revisions to Pediatric Emergency Membership Exception Pathway
- Thoracic – Regional Review Board Guidance for Adult Congenital Heart Disease Exception Requests
Discussion agenda
Fall 2017: Committee presentations
Fall 2017: Summary, Agenda, Data and More
Spring 2017: Public comment presentations
Non-discussion agenda
- Executive – Rewrite of Bylaws Article II: Board of Directors
- Histocompatibility – Histocompatibility Lab Bylaws & Policies Guidance Document